Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma - Scorecard - MDSpire

Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

  • By

  • Caili Zhang

  • Yajuan Yan

  • Xiaojian Li

  • Yong Dong

  • June 18, 2026

  • 0 min

Share

Clinical Scorecard: Clinical Case Study: Management of Hemolytic Anemia and Acute Kidney Injury Following Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin in a Hepatocellular Carcinoma Patient

At a Glance

CategoryDetail
Condition
Key MechanismsOxaliplatin-induced hemolysis and renal impairment (suspected)
Target Population
Care Setting

Key Highlights

  • Patient achieved clinical resolution through exchange transfusion and artificial liver support therapy.

Guideline-Based Recommendations

Diagnosis

  • Exclude other etiologies of hemolysis based on clinical manifestations and laboratory findings (as per case report).

Management

  • Initiate exchange transfusion for severe hemolytic anemia (as per case report).

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      Based on the case study.

      Clinical Best Practices

        Related Resources & Content

        Original Source(s)

        Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma

        • by Caili Zhang, Yajuan Yan, Xiaojian Li, Yong Dong

        • June 18, 2026

        Related Content

        Epstein–Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics

        Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

        The quiet joy of being an oncologist